Please login to the form below

Not currently logged in
Email:
Password:

ViraTherapeutics

This page shows the latest ViraTherapeutics news and features for those working in and with pharma, biotech and healthcare.

Boehringer links up with Trutino for cancer R&D

Boehringer links up with Trutino for cancer R&D

That includes the takeover of oncolytic virus specialist ViraTherapeutics at the end of 2018, which is focused on the latter’s lead candidate VSV-GP, a cancer therapy that works by

Latest news

More from news
Approximately 1 fully matching, plus 5 partially matching documents found.

Latest Intelligence

  • Deal Watch October 2018

    AstraZeneca. Anti-NKG2A antibody (monalizumab), IPH5201 (antibody targeting CD38) and Lumoxiti. #. for hairy cell leukaemia. Development &. commercialisation. collaboration. $307m. ViraTherapeutics/. Boehringer Ingelheim.

  • Deal Watch September 2016 Deal Watch September 2016

    With a headline value of $235m Boehringer Ingelheim entered into a collaboration with ViraTherapeutics to develop an oncolytic virus therapy platform. ... Boehringer also secured the option to acquire ViraTherapeutics after development of VSV-GP. .

More from intelligence
Approximately 0 fully matching, plus 2 partially matching documents found.

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Empowering Strategic Performance Ltd

OUR GOAL: To help clients Metamorph™ Science into Action that changes healthcare to improve the lives of patients. Empowering Strategic...

Latest intelligence

Switzerland
Switzerland: a life sciences hub
Switzerland has a rich diversity of pharma and biotech companies that sustain activity and help maintain its reputation as a highly innovative country...
Responding to dynamic shifts in value communications
OPEN Health’s Beth Lesher and Annemarie Clegg examine what the convergence of medical communications and market access means for pharmaceutical companies....
Doing what we can and having fun doing it: our fundraising month
Charities are facing a number of challenges just to stay afloat amidst the current COVID-19 pandemic. Fundraisers are being cancelled and public donations are not as abundant as they have...

Infographics